Status: Not yet recruiting
Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KER-065 administered to adult and pediatric ambulatory and nonambulatory male participants with Duchenne Muscular Dystrophy (DMD) on stable background therapy.
Participants needed: 36
Trial details
Phase: Phase 2Age: 9+Biological sex: MaleType: InterventionalSponsor: Keros Therapeutics, Inc.Updated: Aug 10, 2026
Eligibility criteria
Diagnosis of DMD, defined as the presence of phenotypic features at screening co... [+8]
Clinical symptoms or signs of cardiomyopathy or heart failure. [+8]